Zeteletinib

Overview

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET , RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T . Zeteletinib has potent antitumor activity.

Application

Products | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > RET | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-139590
• CAS No.: 2216753-97-6
• Molecular Formula: C25H23F3N4O4
• Molecular Weight: 500.47
• Purity: 98.31%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution
• Availability: In-stock

Source

Original product source